ArticleOxford open neuroscience2026
Artificial intelligence in migraine: a narrative review on the diagnostic, prognostic, and therapeutic applications.
Article in Oxford open neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a complex neurological disorder characterized by recurrent and often debilitating headaches, impacting the quality of life for millions worldwide. Over the past decade, artificial intelligence (AI) has emerged as a transformative tool in the field of migraine research and clinical management. This narrative review provides a comprehensive overview of the diagnostic, prognostic, and therapeutic applications of AI in the context of migraine. In the diagnostic realm, AI-based algorithms demonstrate promising capabilities in accurately identifying migraine patterns and subtypes from diverse clinical data sources, including symptom profiles, imaging studies, and genetic markers. These advancements hold the potential for personalized diagnosis and improved patient stratification. Furthermore, AI-powered prognostic models offer the ability to predict migraine progression, anticipate treatment responses, and assess long-term outcomes, thereby aiding in tailored therapeutic decision-making and patient counseling. In therapeutic applications, AI-driven technologies are enabling innovative approaches, including personalized treatment regimens, optimized medication management, and the development of novel therapeutic targets based on big data analytics and predictive modeling. Overall, the integration of AI into the study and management of migraine represents a paradigm shift, holding tremendous promise for advancing precision medicine, enhancing clinical decision support, and ultimately improving the lives of individuals affected by this pervasive neurological condition. This review elucidates the current landscape and future prospects of AI in the multifaceted field of migraine management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.